Latest Breaking News On - Prnewswire partner therapeutics inc - Page 1 : vimarsana.com

Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer

NCI sponsored, ECOG-ACRIN Phase 3 Study of Leukine in Combination with Ipilimumab and Nivolumab in Front Line Treatment of Melanoma Heads to Last Stages of Enrollment

United statesDana farber cancer instituteAhmada tarhiniF stephen hodi jrH lee moffitt cancer centerProfessor of oncologic sciencesMelanoma committeeTanner pharma groupPrnewswire partner therapeutics incClinical translational researchNational cancer institutePartner therapeutics incOncology at dana farber cancer instituteResearch instituteStudy coCancer research group

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Treatment will be Marketed by Nobelpharma Co. Ltd. Under the Trade Name Sargmalin®

United statesRobert mulroyPartner therapeutics incDivision of pioneering advanced therapeuticsNobelpharma coDevice agencyInnovation of niigata university medical dental hospitalJapanese pharmaceuticalsNiigata universityTanner pharma groupPrnewswire partner therapeutics incTrade name sargmalinMedical device agencySponsor investigator koh nakataProject professorPioneering advanced therapeutics

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert mulroyNobelpharma coInnovation of niigata university medical dental hospitalDevice agencyJapanese pharmaceuticalsDivision of pioneering advanced therapeuticsTanner pharma groupNiigata universityPartner therapeutics incPrnewswire partner therapeutics incTrade nameMedical device agencyProject professorPioneering advanced therapeuticsMedical innovation

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

/PRNewswire/ Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device.

United statesRobert mulroyDevice agencyInnovation of niigata university medical dental hospitalJapanese pharmaceuticalsTanner pharma groupDivision of pioneering advanced therapeuticsNobelpharma coNiigata universityPrnewswire partner therapeutics incTrade nameMedical device agencySponsor investigator koh nakataProject professorPioneering advanced therapeuticsMedical innovation

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

United statesRobert mulroyTanner pharma groupNiigata universityDivision of pioneering advanced therapeuticsPrnewswire partner therapeutics incNobelpharma coJapanese pharmaceuticalsDevice agencyPartner therapeutics incInnovation of niigata university medical dental hospitalTrade nameMedical device agencyProject professorPioneering advanced therapeuticsMedical innovation